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Abstract 
Background: Increased expression of the human epididymis protein 4 (HE4) was previously 
described in lung biopsy samples from cystic fibrosis (CF) patients, but it has remained unknown 
whether serum HE4 concentrations are elevated in CF. 
Methods: Seventy-seven children with CF from six Hungarian CF centers and 57 adult CF patients 
from a Czech center were enrolled. In addition, 94 individuals with non-CF lung diseases, and 
117 normal controls without pulmonary disorders were analyzed. Serum HE4 was measured by 
an immunoassay and its expression was further investigated via the quantification of HE4 mRNA 
using RT-qPCR in CF versus non-CF respiratory epithelium biopsies. The expression of the 
potential regulator miR-140-5p was analyzed using an UPL-based RT-qPCR assay. HE4 was 
measured in the supernatants from unpolarized and polarized cystic fibrosis bronchial epithelial 
(CFBE) cells expressing wt- or F508del-CFTR. 
Results: Serum HE4 levels were significantly elevated in children with CF (99.5 [73.1-128.9] 
pmol/L) compared to controls (36.3 [31.1-43.4] pmol/L; P<0.0001). This observation was 
replicated in CF adults (115.7 [77.8-148.7] pmol/L; P<0.0001). In contrast, abnormal but lower 
HE4 concentrations were found in cases of severe bronchitis, asthma, pneumonia or 
bronchiectasis. In CF patients, the concentrations of HE4 were positively correlated with overall 
disease severity and C-reactive protein concentrations, while a significant inverse relationship 
was found between HE4 and the spirometric FEV1 value. Relative HE4 mRNA levels were 
significantly upregulated (P=0.011) with a decreased miR-140-5p expression (P=0.020) in the CF 
versus non-CF airway biopsies. There were 2-fold higher HE4 concentrations in the supernatant 
of polarized F508del-CFTR CFBE cells compared to wt cells. 
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Conclusions: HE4 serum levels positively correlate with the overall severity of CF and the degree 
of pulmonary dysfunction. HE4 may thus be utilized as novel inflammatory biomarker and 
possibly also as measure of treatment efficacy in CF lung disease. 
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Introduction 
Cystic fibrosis (CF) is an autosomal recessive disorders and is linked to a disease-causing 
variation in the CF transmembrane conductance regulator (CFTR) gene 1. CF is a multisystem 
disorder in which abnormal ionic transport mediated by CFTR may lead to alteration of 
properties in the airway surface fluid and mucus 2. The diagnosis of CF is based on typical clinical 
features associated with elevated sweat chloride concentrations, and the detection of 2 CF-
causing CFTR mutations in trans 3,4. More than 2000 genetic alterations have already been 
identified in the CFTR gene with the major p.Phe508del mutation accounting for approximately 
70% of all CF alleles in Hungary and the Czech Republic 5-7. The inflammatory response in 
response to chronic pulmonary infections is related to a number of overexpressed cytokines and 
metalloproteinases that are considered to be major pathogenetic components in CF 8-12.  
Although several diagnostic guidelines have been published for CF within the last two decades 
3,4,13, few studies have employed potential serum biomarkers. These biomarkers may provide 
the desired quantifiable “endophenotype” which could be utilized to monitor disease severity. 
The clinical course of CF could then be indirectly assessed using e.g., increased serum 
concentrations of the C-reactive protein (CRP), interleukin (IL)-1β, and myeloperoxidase 14 that is 
linked to neutrophilia 15, while the measurement of plasma soluble CD14 16, as well as CRP and 
plasma IL-8 17 concentrations might be predictive of pulmonary exacerbations. Cytokine 
concentrations were also thoroughly analyzed in the bronchoalveolar lavage fluid (BALF) 9,18 and 
in sputum samples from CF patients 19. Moreover, tumor markers, such as cancer antigens (CA) 
125 and CA 19-9, were connected with Pseudomonas aeruginosa lung colonization and impaired 
lung function 20, while CA 19-9 may discriminate cases with borderline sweat chloride 
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concentrations 21. However, assessment of various biomarkers has been primarily considered 
within the scientific domain, rather than as part of routine CF laboratory diagnostics. 
The human epididymis protein 4 (HE4) is encoded by the WFDC2 gene 22 and is known to be a 
consistent tumor marker in epithelial ovarian cancers 23,24, lung malignancies 25,26 and 
endometrial carcinomas 27. This protein is a member of the whey acidic protein (WAP) family 
that is homologous to other serine proteinase inhibitors, comprising e.g., elafin and secretory 
leukocyte protease inhibitor (SLPI) 28,29. However, in these mediators different control 
mechanisms, compared to HE4, have been suggested 14. Elafin and SLPI proteins have a major 
role in host defense of the respiratory tract via inhibition of neutrophil elastase (NE) 29 and by 
NFκB activation 30. In this regard, increased SLPI levels were observed in acute respiratory 
distress syndrome 31, and in CF without any concurrent infection. However, SLPI is cleaved and 
down-regulated by NE in the presence of chronic bacterial infections 32,33. Similarly to the WAP 
protein family, HE4 also displays a variety of functions. It acts as an anti-proteinase in the frame 
of epithelial host defenses of the respiratory tract 32,33, and it is involved in sperm maturation 22. 
Although HE4 is overexpressed in the aforementioned tumors, it is also produced by other 
“normal” tissues (e.g., epididymis, salivary glands, prostate, etc.) at baseline levels 32,34. The only 
report on a possible association of HE4 with CF utilized immunohistochemistry for the 
assessment of WFDC2 gene expression (hence HE4) in CF lung biopsy samples containing mainly 
tracheobronchial epithelial cells 14. However, the authors did not analyze HE4 concentrations in 
blood specimens. 
Here, we carried out a multicenter, analyst-blinded, case-control study of two unrelated CF 
populations of various age groups in which we analyzed serum HE4 concentrations. We also 
investigated the possible origin of abnormally high HE4 secretion into the blood via expression 
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analysis of the WFDC2 gene in respiratory epithelium samples by measuring HE4-specific mRNA 
using RT-qPCR. Finally, we examined the level of miR-140-5p as one of the regulatory microRNAs 
of the WFDC2 gene according to a miR database (www.microrna.com). To prove the 
overexpression of HE4 in connection with the CFTR-F508del genotype, supernatant culture 
medium samples from cystic fibrosis bronchial epithelial (CFBE) cells expressing wt- or F508del-
CFTR were obtained for HE4 analysis as an in vitro complementation of the ex vivo 
measurements. 
Material and Methods 
Study participants 
We summarized the main characteristics of all study groups (Table 1), and the demographic and 
laboratory parameters of CF study populations were presented in detail in the Supplementary 
Tables 1 and 2. Seventy-seven young CF patients were consecutively recruited from six 
Hungarian CF centers between October 2012 and February 2015. An independent adult cohort, 
comprising 57 adult CF patients was recruited from an adult CF centre in Prague. All CF subjects 
were diagnosed in accordance with the CF consensus diagnostic criteria [2] and exhibited the 
classic form of the disease. The overall clinical status was assessed by detailed clinical- and 
laboratory examination and “graded” by the Shwachman-Kulczycki (SK) score 8 in those centers 
where it was used, or based on the opinion of clinicians. Accordingly, we categorized the 
patients into these 3 subcohorts. CF individuals with available SK scores of 71-100 were 
classified as ‘mild’, those with 41-70 scores were in the ‘moderate’ category, and subjects with 
≤40 scores were recruited into the ‘severe’ group. Serum samples were collected either during 
routine outpatient clinic visits (these CF patients had predominantly mild to moderate clinical 
course of CF) or during hospitalization due to e.g., acute pulmonary exacerbations 
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demonstrating increased cough with increased sputum production, difficulty in breathing, 
fatigue, and marked decline in lung function results; these criteria were based on Fuchs et al 35. 
CRP concentrations were only analyzed in children with a severe disease course (n=29, 37.6%) 
and in all Czech adults. We also analyzed HE4 after medication at improved clinical states in 10 
CF subjects who appeared at the Outpatient Clinic for a check-up after the recruitment into this 
study. These CF patients were treated by two types of intravenous antibiotics, mucolytic drugs, 
and other anti-inflammatory agents during hospitalization with an average period of 14 days. 
After discharge, these subjects took oral antibiotics for 3 weeks plus inhaled antibiotics for 3 
months.  
In order to assess the underlying non-specific effect of inflammation in other “non-CF“ 
pulmonary diseases on HE4 serum concentrations, 64 patients with severe non-CF lung diseases 
(with chronic bronchitis, asthma or pneumonia). Furthermore, 12 other individuals who had 
non-CF bronchiectasis (n=2) or congenital disease (e.g. Werdnig-Hoffman-syndrome, Williams–
Campbell syndrome, microcephaly, etc., n=7) or treatment resistant severe epilepsy (n=3), were 
also studied. These subjects suffered from severe recurrent lung infections leading to 
bronchiectasis due to repetitive aspiration and bronchial discharge retention. In addition, 18 
non-CF adult subjects who had bronchiectasis or chronic obstructive pulmonary disease (COPD), 
were also recruited. These “clinical controls” were diagnosed using standard X-ray examinations 
and relevant laboratory tests. Exclusion criteria comprised a history of smoking, malignancy, 
immunodeficiency, chronic kidney, or liver disease. There was no significant difference in age 
between the CF and the clinical control cohorts, respectively; however, non-CF patients were 
younger than CF patients (P < 0.05) with a similar gender ratio (Table 1). Bronchial epithelial 
biopsies were obtained via diagnostic bronchoscopy from 3 Hungarian CF subjects (2 M/1 F; 3, 4, 
9 years of age), and 3 other non-CF patients (2 M/1 F; 2, 4, 10 years of age) suffering from 
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repeated episodes of bronchitis (data not shown). Bronchoscopy was performed in the latter 
patients in order to reveal a background of wheezing and to exclude congenital stenosis of the 
main bronchi. Age- and sex-matched children and adult individuals without any apparent 
pulmonary disorders or chronic inflammatory processes were enrolled as random controls 
(Table 1). Finally, 12 apparently healthy parents of Hungarian CF patients (31 [25-37] years of 
age), who were all carriers of p.Phe508del mutation, were also examined for serum HE4 
concentrations (data not shown).  
Ethics statement 
Written informed consent was obtained from the parent(s) or legal guardian of each child and 
adult carriers before the study. The study was approved by the Regional Ethics Committee of the 
University of Debrecen (DEOEC-RKEB/IKEB 3777-2012) and by the Local Ethics Committee of the 
Motol University Hospital, Prague.  
Laboratory diagnosis of CF and the analysis of serum parameters 
Sweat chloride values were analyzed using a Sweat Check Conductivity Analyzer (Wescor, USA). 
Genomic DNA isolation from blood leukocytes was performed with a QIAgen Blood Mini Kit 
(Qiagen, Germany). The 30 most common CFTR mutations in Hungary were tested using a 
Elucigene CF29v2 Kit (Tepnel-Diagnostics, UK) as well as an allele-specific PCR for the ‘Slavic’ 
CFTRdele2,3 (21kb) mutation, as previously described 6.  The Czech adult patient cohort was 
genotyped by the Elucigene EU v3 assay (Tepnel-Diagnostics, UK) and the MLPA kit (MRC 
Holland, The Netherlands). Blood samples for HE4 were obtained by venous puncture, then 
centrifuged, and stored at -70 °C until analysis. Serum HE4 was determined through 
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chemiluminescent microparticle immunoassay (Architect i2000SR, Abbott, USA). Serum CRP was 
measured through electro-chemiluminescent immunoassay (Cobas e411, Roche, Germany).  
Quantification of HE4 mRNA level in airway epithelium biopsies 
Respiratory epithelial cells were kept in isotonic saline at 4 °C in sterile plastic tubes, and 
centrifuged at 1500 g for 5 min, and pellets were stored at -70 °C until analysis. RNA isolation 
was done using Trizol Reagent (Invitrogen, USA) according to the manufacturer’s instructions. 
cDNA was synthesized using 200 ng of total RNA using a High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, USA). RT-qPCR (Light Cycler 480, Roche) was used with 
the SYBR Green PCR Master Mix (Invitrogen) for quantification of the relative expression of the 
HE4 gene in airway epithelial samples. For further details, see Supplementary data. 
Quantification of miR-140-5p expression in airway epithelium biopsies  
MicroRNAs (miRNA) targeting WFDC2 (HE4) gene function were searched by using a prediction 
program (http://www.microrna.org). Since hsa-miR-140-5p was predicted by this algorithm as a 
putative regulator of HE4 gene, this miRNA was selected for further experiments. MiRNA was 
transcribed into cDNA and quantified via miRNA specific RT-PCR reaction using a TaqMan 
MicroRNA Reverse Transcription Kit (Life Technology, USA) according to the manufacturer’s 
instructions. For further details, see Supplementary data. 
HE4 analysis in the supernatants of CFBE cell cultures expressing wt or F508del CFTR 
CFBE 41o- stably expressing either wt-CFTR or F508del-CFTR (a kind gift from Dr. JP Clancy, Dept. 
of Pediatrics, Cincinnati Children’s Hospital, OH) were seeded in triplicate, either in plastic wells 
(250k cells per 3.8 cm2 growth area) or on 12 mm collagen IV-coated Transwell permeable 
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supports (Corning Costar 3460: 250k cells per support) for monolayer formation and 
polarization, which was assessed by daily measurements of transepithelial resistance (TEER). 
Supernatant culture medium samples were taken when confluence (for unpolarized samples) or 
polarization (TEER > 600 Ω/cm2) was reached. The same cells were then treated with LPS 
(L2880, Sigma: 10 μg/ml, 24 h), following which supernatant was once more collected. 
Statistical analysis  
The Kolmogorov-Smirnov test was used for the evaluation of the normality of the data. 
Demographic and laboratory parameters were non-normally distributed thus being expressed as 
median (range), and were analyzed using the Mann-Whitney U test. Normally distributed data of 
RT-qPCR analyses were expressed as mean±SEM and were analyzed by Student’s independent t-
test analysis. The Chi-square test was used to compare categorical variables. The Spearman’s 
rho was calculated for correlation analysis. The discriminative power of HE4 and CRP was 
evaluated using receiver operating characteristics (ROC) curve analysis. P values < 0.05 were 
considered to be statistically significant. All analyses were performed using SPSS Statistics 
software, version 19.0 (IBM Corps., Armonk, NY, USA). 
Results 
Altered laboratory parameters of study populations 
Sweat chloride levels were over 60 mmol/L in most CF individuals (median [range] 107 [90-120] 
mmol/L) except for 7 patients. Of note, this test was not performed in clinical controls and in the 
non-CF group since CF could be conveniently excluded using other tests. Serum CRP was 
increased (reference range: <4.6 mg/L) compared to normal in those young CF subjects with a 
severe clinical status at admission (n=29), in all CF adults and in the groups of non-CF controls 
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(Table 1). In addition, chronic bacterial colonization was detected in 54 young CF and in all adult 
CF individuals. Pancreatic insufficiency and CF-related diabetes mellitus (DM) were diagnosed in 
variable percentages of CF cohorts (Supplementary Tables 1 and 2). 
Highly increased level of serum HE4 in CF regardless of genetic alteration compared to controls 
and non-CF subjects 
Median serum HE4 levels were significantly (P<0.0001) elevated in the 77 CF children and 57 
adult patients with CF compared to normal controls (Table 1 and Fig. 1A). Twenty-nine CF young 
subjects in severe condition had even higher HE4 concentrations (134.9 [124.5-275.0] pmol/L). 
In the adult CF cohort (n=57), there were 13 patients suffering from severe status (170.8 [146.8-
182.9] pmol/L). Gender did not affect HE4 levels in either CF group: in children 95.4 [75-128.5] 
pmol/L in males vs. 101.5 [72.6-129.6] pmol/L in females; P=0.881, while in adulthood median 
HE4 was 119.4 [85.2-150.6] pmol/L in males; 114.8 [75.3-139.1] pmol/L in females; P=0.290 
(data not shown). In terms of CF genetic background, we did not detect differences with variable 
genotypes among children: homozygous for p.Phe508del median HE4 was 99.5 [73.0-127.5] 
pmol/L vs. in the presence of other mutations 94.6 [66.4-127.8] pmol/L, and there was no 
change in HE4 of CF adults between those with p.Phe508del/p.Phe508del (123.1 [74.1-151.1] 
pmol/L) and others with a distinct genetic background (108.3 [83.9-140.0] pmol/L; P=0.348) 
(data not shown). We also analyzed HE4 concentrations in additional patients who suffered 
from severe non-CF lung diseases, such as bronchitis, asthma, pneumonia or bronchiectasis. 
Increased median HE4 level was measured in these cases (P<0.001) compared to normal 
controls, however, these data were much below the results observed in CF (Fig. 1A). More 
importantly, there was a statistically significant difference (P<0.001) in serum HE4 between CF 
and non-CF patients regardless of age. When we sub-grouped non-CF pulmonary young patients 
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based on the types of lung disease, similar changes were seen in severe bronchitis or asthma 
(63.7 [54.1-79.5] pmol/L; n=42) and pneumonia (57.8 [51.2-74.2] pmol/L; n=22) (data not 
shown). Furthermore, we enrolled children suffered from non-CF bronchiectasis due to different 
clinical conditions showing similar HE4 values (80.6 [68.1-134.5] pmol/L) than CF; however, 
median HE4 level was much higher in CF patients. For CF adults, 18 non-CF patients were 
recruited with moderately elevated HE4 (59.2 [41.1-88.6] pmol/L). In contrast, the carriers of CF 
mutations had normal HE4 levels (33.9 [30.1-43.9] pmol/L; n=12). When we determined HE4 
concentration in sputum from CF or other non-CF diseases, - similarly to sera - there were 
significantly higher HE4 concentrations in CF versus non-CF or healthy sputum specimens (see 
Supplementary data and Table 3). 
Serum HE4 in CF is not affected by age and strongly correlates with disease severity  
No significant difference in HE4 was observed among different age groups (P=0.164) (Fig. 1B). 
Age did not seem to have an impact on HE4 levels in these CF patients. In order to investigate if 
serum HE4 can be used as a prognostic disease marker in CF, the relationship between HE4 
levels and disease severity was investigated. HE4 showed a positive trend that followed the 
degree of impairment in both disease cohorts (Figs. 2A and B). Significantly higher HE4 levels 
were seen in CF subjects with a moderate status (108.0 [95.8-133.0] pmol/L; P<0.001) compared 
to those with a mild status (60.8 [50.7-73.8] pmol/L). Even higher HE4 values were measured in 
those in severe condition with an acute exacerbation (134.9 [124.5-275.0] pmol/L; P<0.0001) 
(Fig. 2A). In adult CF, there was a positive correlation between HE4 and disease status: mild 
(72.5 [64.1-94.8] pmol/L), moderate (126.5 [104.3-148.3] pmol/L), and severe clinical symptoms 
(170.8 [146.8-182.9) pmol/L (Fig. 2B). As a preliminary evaluation of HE4 in the follow-up of CF, 
we analyzed HE4 after medication at improved clinical states in 10 CF subjects. Accordingly, 
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there were lower concentrations of serum HE4 (92.5 [87.5-106.2] pmol/L vs. 125.8 [111.8-153.9] 
pmol/L at baseline; P=0.105) after treatment, though results did not reach the range of normal 
controls (data not shown). Of special interest, we recognized a significant negative association 
between HE4 and FEV1 in CF, which was used to evaluate residual lung function capacity 
(Spearman’s rho=-0.522; P<0.0001) (Fig. 3A).  
The association between serum HE4 and CRP in CF 
We sought to analyze if changes in HE4, acting as an additional inflammatory parameter, was 
closely related to the increased levels of CRP. There was a significant and positive correlation 
between serum HE4 and CRP levels in CF children in severe condition plus all CF adults 
(Spearman’s rho=0.595; P<0.001) (Fig. 3B); while no association was observed in patients with 
non-CF lung diseases (Spearman’s rho=0.168; P=0.074) (data not shown). Based on these data, 
increased HE4 can signal massive pulmonary inflammation in CF similarly to CRP. When we 
further compared the laboratory characteristics of HE4 statistically to that of CRP in CF, HE4 
showed a substantial AUC value of 0.724 (95% CI: 0.617-0.830) (P<0.0001), while CRP had an 
average AUC value of only 0.453 (95% CI: 0.347-0.559) (P=0.435). Overall, serum HE4 is able to 
track the development of clinically significant lung inflammation in CF with much higher 
accuracy than CRP. 
The association of serum HE4 with chronic bacterial colonization and CF-related comorbidities  
All adult CF participants had bacterial colonization, thus we could not analyze the relationship of 
HE4 with chronic bacterial infection, while children with positive microbiology tests had 
significantly higher levels of HE4 as compared to those without bacterial colonization (106.5 
[75.8-133.3] pmol/L vs. 78.3 [61.4-96.9] pmol/L; P=0.001). In the presence or absence of CF-
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related DM, no substantial alteration was seen in HE4 (DM: 102.6 [97.8-121.5] pmol/L vs. non-
DM: 91.1 [64.7-128.9] pmol/L; P=0.645). In contrast, pancreatic insufficiency in adults was 
associated with higher serum HE4 values than those with normal pancreatic function (122.2 
[84.1-149.6] pmol/L vs. 96.8 [73.8-108.8] pmol/L; P=0.037) (Supplementary Tables 1 and 2). 
The diagnostic characteristics of HE4 in CF 
We also studied the potential discriminative power of HE4 in the entire study population using 
ROC analyses. Based on the values of the entire CF group, the AUC for HE4 was 0.993 (95% CI: 
0.986-0.999) (P<0.0001) at the 49.3 pmol/L cut-off value for differentiating CF patients from 
normal controls (Fig. 4). The sensitivity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV) for HE4 were 97.0%, 96.6%, 66.5%, and 96.6%, respectively. When the 
AUC for HE4 was calculated for the discrimination of CF from other non-CF pulmonary diseases, 
this value was slightly lower at 0.778 (95% CI: 0.716-0.841) (P<0.0001) with a modest sensitivity 
of 56.0%, but a high specificity of 90.0% at the 98.4-pmol/L cut-off value with 64.6% PPV and 
90.4% NPV (Fig. 4). In addition, we intended to observe if sweat chloride test results showed any 
relationship with serum HE4. Interestingly, a positive and significant correlation was seen 
between the actual level of serum HE4 and the sweat chloride values that were previously 
measured at the diagnosis of CF children (Spearman’s rho=0.345; P=0.005) (data not shown). In 
a subgroup analysis, we analyzed HE4 in those patients (n=8) who had borderline sweat chloride 
test results (30-60 mmol/L) with predominantly mild/moderate clinical conditions. We found 
similar serum HE4 values in these cases (100.9 [88.2-115.0] pmol/L) as seen in the entire CF 
cohort. In summary, serum HE4 was already abnormal when the ‘gold standard’ sweat chloride 
test was only intermediate. Since this was a relatively low number of cases, further evaluation of 
HE4 is necessary in CF with borderline chloride results.  
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Increased level of HE4 mRNA was detected in respiratory epithelium biopsies of CF 
Next, we wanted to investigate the origin of elevated HE4 in CF sera. The goal was to determine 
if HE4 was a consequence of the destruction of the airway epithelium causing an extensive 
release of HE4 due to the massive inflammation, or this protein was produced at a higher 
quantity in the airways. For this purpose, human bronchial epithelium biopsies were obtained 
via bronchoscopy from 3 CF and 3 non-CF patients for controls. HE4 mRNA level in CF was 
significantly upregulated compared to that of non-CF control subjects (HE4/36B4 ratio: 
(mean±SEM) 0.354±0.178 vs. 0.041±0.017; P=0.011; n=3 per group) suggesting that highly 
elevated serum HE4 concentrations in CF may result from its increased secretion by the airway 
epithelium (Fig. 5A). 
The relationship of miR-140-5p with the expression of HE4 in CF 
The level of miR-140-5p was analyzed in the same bronchial epithelial biopsies mentioned above 
from CF and non-CF individuals, and was normalized to RNU43. We observed that miR-140-5p 
expression in CF was significantly decreased compared to non-CF control subjects (miR-140-
5p/RNU43 ratio: (mean±SEM) 0.033±0.008 vs. 0.443±0.076; n=3 per group; P=0.020) (Fig. 5B). In 
order to recognize if there was a strong association with HE4 mRNA and miR-140-5p expression, 
a Spearman’s correlation was performed, which revealed a significant inverse correlation 
between miR-140-5p and HE4 mRNA levels (Spearman’s rho: -0.744, P=0.006) (data not shown). 
F508del-CFTR expressing CFBE cells produced markedly higher HE4 level than those expressing 
wt-CFTR   
HE4 levels in the supernatants of unpolarized and polarized wt- and F508del-CFTR expressing 
CFBE cells were compared. We found that there were about 2-fold higher HE4 concentrations in 
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the supernatants of F508del-CFTR CFBE cells, and the difference was more pronounced in 
polarized cultures compared to unpolarized cells (Fig. 6). Moreover, these cultures were treated 
with LPS (10 μg/mL) for 24 hours in order to analyze the direct effect of bacterial infection on 
HE4 production. We did not, however, observe any induction in HE4 secretion by this 
stimulation (data not shown).  
Discussion 
The lungs are usually most affected in CF, and the patient suffers from recurrent bacterial 
infections and severe inflammation causing destruction in the bronchi, which leads to a reduced 
life expectancy 9. The criteria for the diagnosis of this disease are a positive family history and/or 
abnormal newborn screening test results, typical clinical features, increased sweat chloride test, 
and the identification of 2 CFTR mutations in trans 4. However, there are challenging cases that 
have borderline sweat chloride values or when the genetic analysis reveals zero or only one 
CFTR mutation or mutation(s) with unknown clinical significance. To solve this situation, Sermet-
Gaudelus et al. suggested the use of the nasal potential difference diagnostic score, which was 
found to be a useful tool for inconclusive CF patients 36. Although there are several potential 
blood-based biomarkers for monitoring CF subjects and to identify those who are at a risk of 
acute pulmonary exacerbation, none of them, as yet, have been integrated into routine clinical 
practice 37. Serum MPO, IL-1β, and CRP 15, plasma soluble CD14 16, and plasma IL-8 17 can predict 
pulmonary exacerbation effectively, but only at early time points. No significant association 
between CRP and the severity index of the disease was observed 38.  
HE4 was suggested as a tumor marker for epithelial ovarian cancer 23. Since then, a large 
number of papers supported the superior diagnostic characteristics of HE4 versus CA 125 in this 
particular malignancy 24,39,40 with other possibilities we summarized in a recent review 41. In 
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addition, HE4 may be elevated in certain non-cancer diseases, such as chronic kidney disease 42, 
or in pulmonary tuberculosis where only moderately increased HE4 concentrations were 
reported 43. HE4 was formerly investigated but only in regard to one aspect of CF, i.e., when high 
HE4 expression was described in CF lung biopsies by immunohistochemistry 14. No evidence 
regarding serum HE4 level changes relative to this disease was provided.  
We found that serum HE4 levels were significantly elevated in both young and adult CF patients 
compared to normal controls. There was no difference in HE4 levels between males and 
females, similarly to sweat chloride values as previously described 44. There were a number of 
increased HE4 values in non-CF patients especially in bronchiectasis that partially overlapped 
with a ratio of CF results measured in CF patients, however; the median HE4 concentration was 
much lower than that of CF (Fig. 1A). Within the non-CF group, no significant difference was 
observed when patients were further separated based on subtypes of lung disease. Since the 
non-CF children cohort consisted of younger patients as compared to CF children, we reanalyzed 
the difference in HE4 between CF children and a subgroup of age-matched non-CF children 
cohorts (7.5 [5.0-14.8] years of age), and there were significantly lower HE4 results (56.7 [46.4-
71.6] pmol/L, P<0.0001) in this control group (n=49) in contrast to CF. Very importantly, 
heterozygous healthy parents of some of the studied CF patients showed similar HE4 levels to 
the controls, which is in good agreement with the recessive inheritance of the disease.  
In the adult CF study group, CF patients showed the same HE4 results. We then investigated the 
effect of age on HE4 levels since age could have been a major factor for HE4 41,45. Among our CF 
patients, there was no substantial impact of age on HE4 results (Fig. 1B) in contrast to sweat 
chloride test results that undergo an age-dependent elevation, as exposed in an earlier study 46.  
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Notably, serum HE4 level tightly correlated with bacterial colonization, and pancreatic 
insufficiency. 
HE4 was able to act as a prognostic disease marker in CF when patients were categorized by 
variable degree of severity (Figs. 2A and B). HE4 showed a positive correlation with the degree 
of lung impairment. In this aspect, HE4 was proportionally elevated due to advanced 
inflammatory events. It is noteworthy to mention that this phenomenon is similar to pathologic 
stages in cancers 26,40. 
Previous reports discussed the potential role of CRP in the prediction and detection of 
pulmonary exacerbations with relatively good efficacy 15,17,38. However, this parameter has yet 
to become a routinely used examination in CF. CRP results were abnormal but with a relatively 
modest change in most cases. As most adult patients were infected with P. aeruginosa or B. 
cepacia complex, higher CRP levels were expected even in the stable phase of the disease in 
these patients [35]. Then we compared the diagnostic characteristics of HE4 to CRP. Although 
HE4 showed a larger variation, a positive significant correlation was analyzed between serum 
HE4 and CRP levels in both children and adult study groups. Notably, HE4 in CF had a better 
diagnostic power according to their AUC values in contrast to CRP. In non-CF subjects, this HE4-
CRP association could not be detected. Therefore, serum HE4 can be considered as another 
candidate biomarker for the indication of the accumulation or recurrence of pulmonary 
inflammation and pulmonary exacerbation of CF.  
Treatment options for CF are limited; however, one drug, ivacaftor, has become clinically 
important and has been shown to be very beneficial in some mutations. In clinical studies, 
treatment efficacy was measured using FEV1 and sweat chloride 
47. Testing would also benefit 
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from the use of a biomarker. We believe that measurement of HE4 might serve as a potential 
biomarker for the analysis of treatment in patient follow-up. 
The diagnostic characteristics of HE4 were also evaluated using ROC analyses. The AUC for HE4 
was 0.993 (95% CI: 0.986-0.999) at 49.3 pmol/L cut-off value for differentiating CF patients from 
controls with substantial values of sensitivity, specificity, PPV, and NPV. When the AUC for HE4 
was calculated for the discrimination of CF from other non-CF pulmonary diseases, this value 
was slightly lower 0.778 (95% CI: 0.716-0.841). If one compares HE4 to sweat chloride analysis, 
the ‘gold standard’ test had a much higher PPV (77.1%), but worse NPV (54.8%) at 39 mEq/L 
based on Seia et al. 44. We were curious about the relationship between sweat chloride test 
results and the concentrations of serum HE4. There was a positive significant correlation 
between these parameters in all CF subjects. Serum HE4 was already abnormal when the ‘gold 
standard’ sweat chloride test was only intermediate.  
The origin of increased serum HE4 in CF and other non-cancer diseases has not been studied 
previously. Therefore, HE4 specific mRNA levels in bronchial epithelial biopsies from CF were 
analyzed. In CF, HE4 mRNA levels were significantly elevated compared to non-CF control 
samples; suggesting that high serum HE4 concentrations were a manifestation of increased 
production in the lungs. We recently found WFDC2 among the upregulated genes in a study of 
gene expression in native nasal epithelium of CF that supports the validity of this present data 48. 
Similarly, there were several previous reports on modulated gene expression in mild and severe 
CF due to inflammation with or without bacterial infection or the presence of CFTR mutations 49-
51. Up-regulated genes in mild CF targeted lipid metabolism, G-protein coupled receptor 
expression and ion transports, while in severe CF altered genes were involved in oxidoreductase 
activity and the ubiquitin cycle 50. In terms of classic CF mutations, the p.Phe508del mutation 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 21
was shown to have a minor effect on other gene expression profiles in cell cultures of CF airway 
epithelium cells compared to non-CF cells 51. However, these authors used very stringent cut-off 
statistics as compared to other studies to choose their gene list. 
HE4 levels in the culture medium supernatants of unpolarized and polarized wt and F508del-
CFTR CFBE cells were compared. We found that there were about 2-fold higher HE4 
concentrations in the supernatant of F508del-CFTR CFBE cells in case of polarized cultures as 
compared to wt cells (Fig. 6). Moreover, these cultures were treated with LPS (10 μg/mL) for 24 
hours in order to analyze the direct effect of bacterial infection on HE4 production. We did not 
observe any induction in HE4 secretion by this stimulation. This later data are in agreement with 
the results of Bingle et al. 14 who did not find an alteration in HE4 expression of LPS-treated 
tracheobronchial epithelial cells or type II pneumocytes. Overall, in CF endogenous CFTR 
deficiency may be the main factor for HE4 overexpression, while intrapulmonary 
inflammation/infection may be supplemental in HE4 secretion. 
Certain cytokines such as IL-8 are present with increased concentrations in the BALF obtained 
from CF patients, while others (e.g. IL-10) are at relatively lower quantity versus non-CF samples 
52. For instance, elevated levels of IL-8 have been shown to be selectively produced by airway 
epithelium and recruited neutrophils in CF 53, with neutrophil elastase being a key mediator of 
its production 54. A quantitative gene expression analysis was processed where IL-8 mRNA level 
was increased in ex vivo bronchial epithelial cells 49. By measuring the expression of other genes, 
additional explanations for the development of CF phenotype could be revealed in connection 
with e.g. airway defense 50. Recently, miRNAs with aberrant expression seem to be potential 
regulators of the disease pathomechanism 55. Out of hundreds of miRNAs, 56 showed decreased 
levels, while 36 were up-regulated in CF versus non-CF samples 55. Notably, miR-126 was found 
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to be down-regulated in CF airway epithelial cells that regulate the innate immune (TH2) 
response via TOM1 expression in the TLR2/4 signaling pathway 56. miR-155 was responsible for 
the overexpression of IL-8, and bacterial infection promoted the expression of other miRNAs 
such as miR-215 57.  
In this study, we analyzed the level of miR-140-5p in connection with CF. This particular 
microRNA showing a high nucleotide complementarity to the HE4 specific mRNA target, has 
been recently studied in several types of malignancies, such as in non-small cell lung cancer 58. 
Based on those data, the monocyte to macrophage differentiation-associated (MMD) gene was 
targeted by miR-140-5p that enhanced proliferation of lung tumor cells via ERK signaling 58. 
According to a miRNA-related database, miR-140-5p was predicted to be associated with 
WFDC2/HE4 gene expression. We found that the level of miR-140-5p in respiratory epithelium 
biopsies was significantly decreased compared to non-CF control individuals, and was negatively 
associated with HE4 mRNA levels. Overall, lower levels of miR-140-5p - at least in part - may 
contribute to the exaggerated production of HE4 protein via higher HE4 mRNA expression in 
airway epithelium. Further investigations are needed to prove this relationship. 
HE4 exhibited a proteinase inhibitory activity towards trypsin, elastase, matrix metallopeptidase 
9, and the secretory proteinases from Bacillus subtilis 59. Accordingly, we suppose that HE4 as an 
immunological response to bacterial/inflammatory events may show an inhibitory effect in this 
disease. Moreover, HE4 was described as a fibroblast-derived mediator of kidney fibrosis 60. 
Accordingly, we speculate that increased HE4 may also contribute to fibrotic degradation of the 
lung in CF. Further experiments are required to support these theories.  
The finding that HE4, a well-described tumor marker, is found up-regulated in CF, may be linked 
to a less differentiated epithelial state previously described in CF versus non-CF cells 61. Indeed, 
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our own meta-analysis of data of gene expression profile revealed that CF nasal cells' have a 
significant overlap with genes related to undifferentiated epithelial phenotype 62.  
In conclusion, serum HE4 is elevated in CF and correlates with the severity of the disease, thus it 
has the potential to be utilized as a novel prognostic biomarker that detects pulmonary 
inflammation. However, further studies are needed to clarify if released HE4 plays any 
functional role relative to IL-8, NE or any metalloproteinases in the regulation of local 
inflammatory lung events of CF patients. 
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Figure legends 
 
 
Fig. 1. Serum HE4 levels in CF, non-CF, and normal controls (A). There were significantly 
increased HE4 concentrations in CF children compared to both controls and non-CF individuals; 
however, some elevation was also seen in non-CF subjects versus controls. Investigation of the 
effect of age on HE4 levels (B). The following HE4 concentrations were found in these sub-
cohorts: 1-4 years of age (n=11): 122.7 [80.7-130.8] pmol/L; 5-9 years of age (n=19): 113.7 [82.6-
190.3] pmol/L; 10-14 years of age (n=21): 91.1 [75.0-121.6] pmol/L; 15-18 years of age (n=26): 
83.0 [64.4-112.1] pmol/L; 19-22 years of age (n=20): 107.6 [80.5-142.1] pmol/L; 23-29 years of 
age (n=24): 120.7 [81.1-120.7] pmol/L; 30-40 years of age (n=13): 115.7 [77.8-146.9] pmol/L. We 
did not find a significant difference in HE4 between these age groups. 
 
Fig. 2. Correlation of HE4 with the clinical status of CF patients. CF children were categorized 
into 3 groups at the time of study recruitment showing mild (n=30), moderate (n=18), and 
severe (n=29) symptoms (A). Similar categorization was done in adults with CF with mild (n=22), 
moderate (n=22), and severe (n=13) states (B). Serum HE4 gradually increased in relative 
worsening conditions. 
 
Fig. 3. The relationship between HE4 and FEV1 (A) and serum CRP (B) values. There was a 
statistically significant inverse association (P<0.0001) between HE4 and FEV1 values suggesting 
that HE4 was highly correlated with the degree of lung dysfunction (A). In contrast, HE4 was 
strongly associated wit CRP parameters in CF (B).  
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Fig. 4. ROC analysis of HE4 in the differentiation of CF from normal controls (with triangles) and 
CF from other non-CF lung diseases (with full circles). Substantial AUC values were calculated, 
and the 49.3 pmol/L cut-off value differentiated CF patients from normal controls, while the 
98.4 pmol/L cut-off value was determined to distinguish CF from other pulmonary conditions. 
 
Fig. 5. Analysis of the level of HE4 mRNA in bronchial epithelium biopsies obtained via 
bronchoscopy from 3 CF and 3 non-CF patients (A). RT-qPCR was assessed to quantify and 
compare HE4 mRNA expression. We found that HE4 mRNA concentrations were significantly up-
regulated in CF versus non-CF control samples. HE4 mRNA level was normalized to the 
expression of the reference gene 36B4. Data are expressed in this ratio in mean±SEM. Analysis 
of relative miR-140-5p expression in respiratory epithelium biopsies obtained from CF and non-
CF patients. The miRNA level was normalized to RNU43. We observed a significantly decreased 
level of miR-140-5p in CF compared to non-CF control samples. Data are expressed as a ratio to 
RNU43 in mean±SEM (B). 
 
Fig. 6. The measurement of HE4 level in the supernatants of unpolarized and polarized wt and 
F508 deficient CFBE cells. There was about 2-fold higher HE4 level in the supernatant of 
F508del-CFTR cells in polarized cultures as compared to wt cells. n=3 per each type of sample.  
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Age           
(years) 
Gender   
(m/f; n) 
Serum HE4         
(pmol/L) 
Serum CRP         
(mg/L) 
Young CF patients (n=77)  11 (7-17) 37/40 99.5 (73.1-128.9) 5.3 (2.0-9.3)
#
 
Adult CF patients (n=57) 25 (21-29) 26/31 115.7 (77.8-148.7) 14.3 (12.9-27.0) 
Non-CF young patients (n=76) 6 (3-14) 32/44 63.9 (54.3-83.4) 7.5 (1.1-18.2) 
Non-CF adult patients (n=18) 26 (23-38) 7/11 59.2 (41.0-88.6) 8.9 (3.1-15.7) 
Young controls (n=77) 13 (10-15) 33/44 36.3 (31.1-43.4) nm 
Adult controls (n=40) 25 (23-38) 17/23 33.8 (29.8-38.6) nm 
 
Table 1. Demographic and laboratory parameters of study populations. Data are expressed as median value (range). Serum CRP was 
measured in 29 individuals with severe clinical conditions out of 77 young CF-subjects marked with #. nm means ’not measured’. 
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List of abbreviations: CF, cystic fibrosis; HE4, human epididymis protein 4; CFTR/CFTR, cystic 
fibrosis transmembrane conductance regulator/gene; CFBE, cystic fibrosis bronchial epithelial; 
CRP, C-reactive protein; BALF, bronchoalveolar lavage fluid; SK-score, Shwachman-Kulczycki 
score; FEV1, forced expiratory volume in one second; NE, neutrophil elastase, TEER, 
transepithelial resistance 
 
